| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | RAF265 | CTRPv2 | pan-cancer | AAC | 0.0095 | 0.8 |
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | 0.0088 | 0.8 |
| mRNA | GMX-1778 | CTRPv2 | pan-cancer | AAC | -0.0081 | 0.8 |
| mRNA | CCT036477 | CTRPv2 | pan-cancer | AAC | -0.0076 | 0.8 |
| mRNA | BRD-K09344309 | CTRPv2 | pan-cancer | AAC | 0.018 | 0.8 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | -0.007 | 0.8 |
| mRNA | BRD-K48477130 | CTRPv2 | pan-cancer | AAC | -0.013 | 0.8 |
| mRNA | GSK4112 | CTRPv2 | pan-cancer | AAC | -0.0083 | 0.8 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | -0.0081 | 0.8 |
| mRNA | pifithrin-mu | CTRPv2 | pan-cancer | AAC | -0.0078 | 0.8 |